🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to researchers.

An International Challenge

Gonorrhoea infections are escalating around the world, with data suggesting in excess of 82 million instances per year. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The WHO has classified it as a "critical concern". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization marks a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Results and Worldwide Availability

According to data published in a major medical journal, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which involves an injection and a pill. The study included over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to make available and distribute the drug in many low-income and middle-income countries.

Doctors treating patients have expressed hope. The availability of a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the illness for patients and to stop the proliferation of untreatable gonorrhoea globally.